Thursday, June 27, 2019

ZEE5 Associates with India’s Growing OTT Platform

ZEE5, India’s fastest growing OTT platform ties up with, one of India’s most successful e-pharma portals, to treat its users with exciting ZEE5 subscription offers. This will enable Netmeds’ customers to access the unlimited content choices on the OTT platform.

After tying up with players across multiple sectors such as travel and payment gateways, this is a first for ZEE5 – partnering with health-tech company. With this association, Netmeds’ customers making a first- time purchase of medicines or non-prescription OTC products will receive a complimentary ZEE5 1-month premium subscription pack. In addition, existing Netmeds’ customers will receive a flat 30% discount on any premium pack of ZEE5.

Manish Aggarwal, Business Head, ZEE5 India said, “At ZEE5, we are focussed on growth while delivering exceptional value to our viewers. This partnership is in line with ZEE5’s agenda of expanding its reach to a wider set of audience. Our philosophy behind this is that a wholesome menu of entertainment can be the perfect panacea for an unwell person. Netmeds’ customers can now enjoy a hearty dose of entertainment at a special pricing.”

Anand Pathak, Director-Marketing, said, “Netmeds is thrilled to partner with ZEE5 and offer quality entertainment along with delivering quality medicines across the country. It has been our constant endeavor to keep customers happy by providing affordable healthcare products & services at competitive pricing. And this partnership will further enhance the customer experience by allowing them to avail rich content as a value-added service while purchasing medicines online on”

With over 3500 films, 500+ TV shows, 4000+ music videos, 35+ theatre plays and 90+ LIVE TV Channels across 12 languages, ZEE5 truly presents a blend of unrivalled content offering for its viewers across the nation and worldwide. With ZEE5, the global content of Zindagi as a brand, which was widely appreciated across the country, has also been brought back for its loyal viewers.

No comments:

Total Pageviews